Invasive Cardiology

Digital Edition

DIGITAL EDITION

Interactive BONUS content delivered to your email

CLICK HERE TO CONTINUE »





CLINICAL EVENTS CALENDAR

Non-Accredited Education

CLINICAL EXPERIENCE WITH A NEW HYBRID CORONARY WIRE
On Demand Web ArchiveNon-Accredited
Target Audience: Physicians, nurses, and technologists.
This activity is supported by an educational grant from Terumo Medical Corporation.

Frugal Coronary Angioplasty, Still an Option after 30 Years

Figure 1. (A) Stenosis in the left anterior descending artery of the world’s first patient to undergo percutaneous coronary intervention by Andreas
Grüntzig in Zürich on September 16, 1977, when the patient and his doctor were both 38 years of a(F) Reinserting the catheter
into the left coronary artery,
the same 2.5 mm balloon and
coronary guidewire were used
to dilate the left circumflex
branch, which showed a good
result at the site itself (arrow),
but a spiral dissection (small
arrows) more dTable 1. History of interventional cardiology.
Table 2. World experience with percutaneous coronary intervention
as of August 1980 (818 cases total).*Table 3. Percutaneous coronary intervention results of Andreas
Grüntzig and his intimate collaborators from Case 1 (September 16,
1977) to his death (October 25, 1985). Courtesy of Gary Roubin, MD.Table 4. Percutaneous coronary interventional devices and techniques
1977–2008Table 5. Devices and techniques used in the case described.
(B) Last available follow-up
angiogram 23 years later with an excellent result (arrow).(C) Exercise bicycle stress test shortly after the 30-year anniversary of the intervention
showing a normal electrocardiogram (apart from a preexisting right bundle-branch block) at peak exercise of 167 Watt with a peak heart rate of 149
beats per minuteFigure 2. A 53-year-old office worker experienced unrelenting chest pain that began 3 hours prior to emergency cardiac catheterization while
trimming a tree, crouched on a ladder. His only risk factor was smoking and he presented with inferior ST-segment(B) The catheter was then placed into the left coronary artery that was
assumed to be the nonculprit vessel. Surprisingly, a subtotal stenosis of
a large anterolateral marginal branch was found (arrow). This clearly
did not fit with the hypokinesia andFigure 2 (continued). (C) The AL-2 catheter was then flipped
across to the right coronary artery. There, the culprit lesion was
found in the form of a fairly long thrombus saddling the crux of the
dominant right coronary artery (arrows). In addition, t(D) Using a single coronary guidewire and a 2.5 mm balloon, gentle
dilatation at the crux was performed, resolving the local problem (arrows),
while the more distal occlusion (arrowhead) remained the same.
Figure 2 (continued). (G) A 2.5 x 18 mm Cypher™ stent was
implanted to finish treatment of the marginal branch (arrows) of the
left circumflex coronary artery. The dye still stagnated in the right
coronary artery (arrowhead).(H) While waiting for the abciximab to clear out the right coronary
artery, a 6 Fr multipurpose catheter was introduced into the right
femoral vein (without an introducer) and a dye injection revealed the
suspected presence of a patent foramen ovale (PFO)(E) It was decided to wait for the effect of abciximab and fix the
problem in the left circumflex coronary artery in the mean time.
However, the patient developed complete atrioventricular block
and symptomatic bradycardia, which was immediately reversed(I) The AL-2 5 Fr catheter was then readvanced into the right coronary
artery, this time showing that abciximab had recanalized the distal
portion of the posterolateral branch (arrows). Venous access was used
to insert a temporary pacemaker lead into the(J) The 2.5 mm balloon and coronary guidewire were used a final
time to dilate this lesion with a good angiographic result (arrows).
After this, all catheters, including the temporary pacemaker lead, were
removed and the groin was held for 10 minutes to a



VOLUME: 20 PUBLICATION DATE: Apr 01 2008
Sidebars_in_article: 
Issue Number: 
4 (April 2008)
author(s): 

Bernhard Meier, MD

Coronary angioplasty was not the first interventional procedure in cardiology (Table 1), but it clearly launched the discipline called interventional cardiology as we know it today.
Percutaneous coronary intervention (PCI), as it is customarily called today, had a slow start. Three years into its existence, the world experience still totaled less than 1,000 interventions (Table 2). Andreas Grüntzig showed impressively and unmistakably that PCI could be applied in a successful and safe manner even before the development of stents. The first case showing a good result up to the current day (Figure 1) may be considered anecdotal. However, Andreas Grüntzig’s lifetime series, cut short by his demise 5 months before the first coronary stent implantation, 1 confirms it unequivocally. He and his close collaborators performed more than 2,000 balloon-only procedures without any in-hospital mortality (Table 3).

PCI has seen lots of adjunctive therapies and even so-called balloon replacement therapies over the past 30 years. Few have prevailed, and even today, what is really important boils down to 5 components: state-of-the-art balloons, guidewires, guiding catheters, X-ray equipment, and stents. Add to these novel antiplatelet agents and perhaps percutaneous left ventricular assist devices that save an occasional life in large-volume centers (Table 4). Techniques to close the femoral puncture site are important comfort items for both physician and patient. All of the other presumable assets were either useless (some even dangerous) or remain completely optional. Nonetheless, many of them have made it into routine use in most catheterization laboratories.
Even the coronary stent is clearly overused these days. First it went through a difficult initial phase where its 20% thrombosis rate was not sufficiently corrected for the situations in which the stents were used (bailout for impending or established abrupt closure), but rather compared with the 7% thrombosis rate of plain balloon angioplasty. This bane vanished when stents were implanted mostly in elective cases. Erroneously, the drastically decreasing stent thrombosis rate was not initially attributed (as it should have been) to the transition from bailout to elective stenting, but rather to changes in implantation techniques (higher pressures) and the addition of a second antiplatelet agent (thienopyridine). The latter contributed to improvement in stenting results, but only to a minor degree.

The community of angioplasty operators then went to the other extreme and made stenting the default procedure, turning a completely blind eye on the fact that without stents, at least 70% of lesions never had a problem, neither acutely nor during follow up. In these 70% of patients (who of course never ceased to exist), a stent cannot be of any benefit, but it can harm during the “unnecessary” implantation, or it can harm during follow up by creating in-stent restenosis that is much more difficult to treat than restenosis after plain balloon angioplasty or by late thrombosis, unseen after balloon angioplasty. As soon as default stenting was ubiquitously adopted, the initial advantage of stenting in terms of survival and avoidance of myocardial infarctions due to abrupt vessel closure was lost again during mid-term follow up. The advent of drug-eluting stents basically eliminated the problem of in-stent restenosis. Strangely, when for a while their safety was questioned, people considered a fallback to bare-metal stents, but not to plain balloon angioplasty, though only the latter completely precludes late thrombosis.

A temporary setback of PCI is currently witnessed in light of the falsely-accused drug-eluting stent and the falsely-interpreted comparisons between PCI and conservative treatment in the Mass II,2 PET and COURAGE trials.4 These trials found no difference in survival or instances of myocardial infarctions in stable coronary patients treated with either PCI (i.e., bare-metal stenting) or medical therapy plus PCI only when symptoms did not abate. The interpretation that this meant PCI was not warranted cannot be condoned. In contrast, the trials should be interpreted such that in spite of having repaired the problem in the group that underwent PCI, the mid-term outcomes were not worse, although the PCI-arm patients already had all the possible problems from the intervention behind them, whereas the conservative group still had them ahead of them. In other words, if you know your brakes need fixing, you may well drive on for a certain time without fixing them. The fact that you did not have an accident does not mean that your brakes never needed fixing.
These storms in a teacup could, however, have called us back to reason that, yes, we should do the interventions but, no, we should not fall victim to the temptation of overdoing things. The case in Figure 2 shows that interventional cardiology can do complex things with rather frugal techniques and materials.5 Table 5 is a summary of procedures conducted in this patient and the material used. The patient was released 3 days postprocedure.
   

References: 

References 1. Puel J, Lacapere B, Sabathier M, et al. Coronary revascularization at the acute phase of myocardial infarction. Short and median-term survival of 359 patients. Multicenter study. Arch Mal Coeur Vaiss 1986;79:409–417.
2. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): A randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: One-year results. J Am Coll Cardiol 2004;43:1743–1751.
3. Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: A randomized trial. Circulation 2004;109:1371–1378.
4. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503–1516.
5. Meier B. Frugal coronary angioplasty. In: Meier B (Ed). Interventional Cardiology: An Atlas of Investigation and Therapy. Oxford, United Kingdom: Clinical Publishing. 2004, pp. 21–43.

Average: 5 (1 vote)


Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <code> <ul> <ol> <li> <dl> <dt> <dd><br><h1><h2><h3><b><i>
  • Lines and paragraphs break automatically.

More information about formatting options


All Subscriptions are FREE to qualified cardiology professionals

#

  • Subscribe to:
  • Journal
  • Digital Journal
  • E-News
  • RSS feed

CLICK HERE TO CONTINUE »

Newly Revised and Updated for 2009!

practical EP



Press Release


FDA Clears Invatec's Mo.Ma Ultra Proximal Cerebral Protection Device

— Bethlehem, Pennsylvania – Invatec received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October to market its Mo.Ma Ultra Proximal Cerebral Protection Device for use during carotid artery stenting (CAS). The device effectively reduces and captures debris released during the stenting procedure to prevent it from traveling to the brain, where it has the potential to cause a stroke.


CME Showcase


The Use of Remote Robotic Navigation
in Complex Arrhythmias

Complimentary Accredited Web Archive
This activity is designed for electrophysiologists and EP allied professionals.

Diagnosing Coronary Artery Disease: Advanced Cardiovascular Imaging Solutions

Complimentary accredited web archive
This activity is intended for physicians, nurses, and technologists.



New Standards of Care for CRMD Antibiotic Protection
Complimentary CME Accredited Webcast
Dates: November 18, 2008 Time: 6:00 pm ET November 19, 2008 Time: 3:00 pm ET
This activity is sponsored by the North American Center for Continuing Medical Education.

REVIEW OUR OTHER
CARDIOLOGY BRANDS
Check out our other resources for healthcare professionals of all specialties.

  • CathLab Digest
  • EP Lab Digest
  • Vascular Disease Management